In February 2022, the White House announced the reignition of the Cancer Moonshot Initiative with the goals of reducing the death rate from cancer by at least 50% over the next 25 years and improving the experience of people and their families living with and surviving cancer. A core component of the Cancer Moonshot Initiative is the facilitation of multisector partnerships to solve the compelling challenges faced in cancer care delivery. The American Cancer Society (ACS) has a longstanding tradition of convening partners across the cancer landscape, most notably through conferences, partner meetings, advocacy coalitions, and coalescing of thought leaders through roundtables. For example, the ACS and several patient advocacy organizations, scientific organizations, and pharmaceutical partners came together in October 2022 to launch the new ACS National Breast Cancer Roundtable and the ACS National Cervical Cancer Roundtable as “all-hands-on-deck” coalitions to reshape cancer care.¹ These Roundtables aim to both (1) identify the leading challenges in detection and treatment within these cancers and (2) provide expert guidance to providers, patients, payers, and policy makers regarding evolutions needed to increase access and patient centricity of cancer care. Beyond disease-specific issues, the ACS and its partners have also explored topics that span the cancer care continuum.

Currently, much of the attention given to innovation in oncology is centered upon creating and delivering a rapidly expanding armamentarium of anticancer treatments. Efforts to develop more novel, personalized, and targeted therapies have been fruitful but also continue to further highlight issues related to access. How treatments are selected and delivered and how outcomes are monitored require additional focus. Furthermore, how such efforts align with increasing calls for patient centricity, meeting patients where they are both figuratively and literally, requires a national discussion. Herein, we describe the findings from the first effort of the ACS in convening national leaders across multiple stakeholders, including the provider, payer, government, and technology communities, to discuss cancer care delivery at home.

2022 年 2 月，白宫宣布重新启动癌症登月计划，目标是在未来 25 年内将癌症死亡率降低至少 50%，并改善癌症患者及其家人的体验。癌症登月计划的核心组成部分是促进多部门伙伴关系，以解决癌症护理服务中面临的严峻挑战。美国癌症协会 (ACS) 有着召集癌症领域合作伙伴的悠久传统，最引人注目的是通过会议、合作伙伴会议、倡导联盟以及通过圆桌会议凝聚思想领袖。例如，ACS 和一些患者权益组织、科学组织、¹这些圆桌会议的目的是 (1) 确定这些癌症检测和治疗方面的主要挑战，以及 (2) 为医疗服务提供者、患者、付款人和政策制定者提供关于增加癌症护理的可及性和以患者为中心所需的演变的专家指导。除了特定疾病的问题之外，ACS 及其合作伙伴还探讨了跨越癌症护理连续体的主题。

目前，对肿瘤学创新的大部分关注都集中在创建和提供快速扩展的抗癌治疗手段上。开发更新颖、个性化和靶向疗法的努力取得了丰硕成果，但也继续进一步凸显与获取相关的问题。如何选择和实施治疗以及如何监测结果需要额外关注。此外，这些努力如何与日益增长的以患者为中心的呼声相一致，无论是象征性还是字面意义上的满足患者的需求，都需要进行全国性的讨论。在此，我们描述了 ACS 首次召集多个利益相关者（包括提供者、付款者、政府和技术界）的国家领导人讨论家庭癌症护理服务的结果。